10月15日，再生元制药公司盘中上涨3.58%，报797.04美元，成交额7375.49万美元。
当日股价异动的直接催化来自机构评级上调。瑞银恢复覆盖该股并给予买入评级，认为重磅药物Dupixent的潜力被市场低估，带动资金情绪回暖。
此外，公司近期基本面消息亦提供支撑。Pasatru在OPTIMA三期试验84周扩展结果中继续显示持续疗效且安全性与56周结果一致；该药已于8月获FDA批准用于成人FOP，长期数据进一步强化其商业化前景。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.